GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (OTCPK:INRLF) » Definitions » Shiller PE Ratio

Valneva SE (Valneva SE) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Valneva SE Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Valneva SE Shiller PE Ratio Historical Data

The historical data trend for Valneva SE's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Shiller PE Ratio Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.77 - - - -

Valneva SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Valneva SE's Shiller PE Ratio

For the Biotechnology subindustry, Valneva SE's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Valneva SE's Shiller PE Ratio falls into.



Valneva SE Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Valneva SE's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Valneva SE's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.446/119.4700*119.4700
=0.446

Current CPI (Mar. 2024) = 119.4700.

Valneva SE Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.122 100.180 -0.145
201409 -0.064 99.920 -0.077
201412 -0.247 99.860 -0.296
201503 0.152 100.170 0.181
201506 -0.135 100.440 -0.161
201509 -0.079 99.950 -0.094
201512 -0.239 100.040 -0.285
201603 -0.078 100.020 -0.093
201606 -0.517 100.630 -0.614
201609 -0.101 100.340 -0.120
201612 -0.042 100.650 -0.050
201703 -0.021 101.170 -0.025
201706 -0.034 101.320 -0.040
201709 -0.048 101.330 -0.057
201712 -0.059 101.850 -0.069
201803 0.025 102.750 0.029
201806 -0.023 103.370 -0.027
201809 -0.047 103.560 -0.054
201812 0.091 103.470 0.105
201903 0.056 103.890 0.064
201906 -0.090 104.580 -0.103
201909 0.000 104.500 0.000
201912 0.011 104.980 0.013
202003 -0.011 104.590 -0.013
202006 -0.302 104.790 -0.344
202009 -0.483 104.550 -0.552
202012 -0.024 104.960 -0.027
202103 -0.357 105.750 -0.403
202106 -0.735 106.340 -0.826
202109 -1.882 106.810 -2.105
202112 1.989 107.850 2.203
202203 -0.264 110.490 -0.285
202206 -1.416 112.550 -1.503
202209 0.653 112.740 0.692
202212 -0.339 114.160 -0.355
202303 -0.139 116.790 -0.142
202306 -0.130 117.650 -0.132
202309 -0.267 118.260 -0.270
202312 -0.251 118.390 -0.253
202403 0.446 119.470 0.446

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Valneva SE  (OTCPK:INRLF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Valneva SE Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Valneva SE's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (Valneva SE) Business Description

Traded in Other Exchanges
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.